Phase I Study of GRN1005 in Recurrent Malignant Glioma
Abstract
PURPOSE: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. METHODS: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. RESULTS: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m(2) every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m(2) every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥ 420 mg/m(2) had stable disease, which lasted a median of 51 days. Therapeutic concentrations of GRN1005 and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥ 200 mg/m(2). CONCLUSION: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m(2) every 3 weeks.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LRP1 is highly expressed on glioma cells.
“Besides on the BBB, LRP1 was also found to be highly expressed on glioma cells39–41.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [39]
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 4,201 · see citing works
Self-citationBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · see citing works
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567 · see citing works
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · see citing works
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.
Aronen, H. J., Gazit, I. E., Louis, D. N., Buchbinder, B. R., Pardo, F. S., Weisskoff, R. M., Harsh, G. R., Cosgrove, G. R., Halpern, E. F., & Hochberg, F. H. (1994) · Radiology · doi:10.1148/radiology.191.1.8134596 · Cited by 905 · see citing works
Lillis, A. P., Duyn, L. B. V., Murphy-Ullrich, J. E., & Strickland, D. K. (2008) · Physiological Reviews · doi:10.1152/physrev.00033.2007 · Cited by 702 · see citing works
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · see citing works
Self-citationWick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518 · see citing works
Kounnas, M. Z., Moir, R. D., Rebeck, G. W., Bush, A. I., Argraves, W. S., Tanzi, R. E., Hyman, B. T., & Strickland, D. K. (1995) · Cell · doi:10.1016/0092-8674(95)90320-8 · Cited by 489 · see citing works
Identification and Design of Peptides as a New Drug Delivery System for the Brain
Demeule, M., Régina, A., Ché, C., Poirier, J., Nguyen, T., Gabathuler, R., Castaigne, J., & Béliveau, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131318 · Cited by 464 · see citing works
Self-citationPardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 450 · see citing works
Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier
Fillebeen, C., Descamps, L., Dehouck, M., Fénart, L., Benaı̈ssa, M., Spik, G., Cecchelli, R., & Pierce, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7011 · Cited by 385 · see citing works
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 370 · see citing works
Self-citationTransport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15451 · Cited by 359 · see citing works
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215451 · Cited by 359 · see citing works
Crown, J. P., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 353 · see citing works
Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors
Meyers, C. A., & Brown, P. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6086 · Cited by 350 · see citing works
Self-citationThomas, F. C., Taskar, K. S., Rudraraju, V., Goda, S., Thorsheim, H. R., Gaasch, J. A., Mittapalli, R. K., Palmieri, D., Steeg, P. S., Lockman, P. R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9964-5 · Cited by 227 · see citing works
High transcytosis of melanotransferrin (P97) across the blood–brain barrier
Demeule, M., Poirier, J., Jodoin, J., Bertrand, Y., Desrosiers, R. R., Dagenais, C., Nguyen, T., Lanthier, J., Gabathuler, R., Kennard, M. L., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01201.x · Cited by 222 · see citing works
Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier
Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Moghrabi, A., & Béliveau, R. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00201-x · Cited by 220 · see citing works
Maletı́nská, L., Blakely, E. A., Bjornstad, K. A., Deen, D. F., Knoff, L. J., & Forte, T. M. (2000) · PubMed · Cited by 205 · see citing works
Analysis and interpretation of data
(2014) · Routledge eBooks · doi:10.4324/9781315838946-11 · Cited by 193 · see citing works
Metabolic and hemodynamic evaluation of gliomas using positron emission tomography.
Tyler, J. L., Dikšić, M., Villemure, J., Evans, A. C., Meyer, E., Yamamoto, Y., & Feindel, W. (1987) · PubMed · Cited by 185 · see citing works
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S. L., Smith, C. S., Brenner, A. J., Sankhala, K. K., Mita, A. C., Elian, K., Bouchard, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 181 · see citing works
Self-citationBenchenane, K., Bérézowski, V., Ali, C., Fernández‐Monreal, M., López‐Atalaya, J. P., Brillault, J., Chuquet, J., Nouvelot, A., MacKenzie, E. T., Bu, G., et al. (2005) · Circulation · doi:10.1161/01.cir.0000163542.48611.a2 · Cited by 178 · see citing works
Kemper, E. M., Boogerd, W. J., Thuis, I., Beijnen, J. H., & van Tellingen, O. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.001 · Cited by 177 · see citing works
Blood−brain barrier transporters and response to CNS-active drugs
Urquhart, B. L., & Kim, R. B. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0714-8 · Cited by 175 · see citing works
Wolf, B. B., Lopes, M. B. S., VandenBerg, S. R., & Gonias, S. L. (1992) · PubMed Central · Cited by 174 · see citing works
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Lee, E. Q., Norden, A. D., Drappatz, J., Muzikansky, A., Doherty, L. M., LaFrankie, D. C., Ciampa, A. S., Kesari, S., & Wen, P. Y. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-006 · Cited by 170 · see citing works
Self-citationEfficient transfer of receptor-associated protein (RAP) across the blood-brain barrier
Pan, W., Kastin, A. J., Zankel, T. R., van Kerkhof, P., Terasaki, T., & Bu, G. (2004) · Journal of Cell Science · doi:10.1242/jcs.01381 · Cited by 153 · see citing works
Sadeghi, N., D’Haene, N., Decaestecker, C., Levivier, M., Metens, T., Maris, C., Wikler, D., Balériaux, D., Salmon, I. J., & Goldman, S. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0851 · Cited by 148 · see citing works
Paclitaxel (TAXOL®) concentrations in brain tumor tissue
Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C., Meijer, O. W. M., TAPHOORN, M. J. B., & Beijnen, J. H. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058736 · Cited by 131 · see citing works
Tissue distribution, metabolism and excretion of paclitaxel in mice
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199601000-00009 · Cited by 128 · see citing works
Cytotoxicity of taxol in vitro against human and rat malignant brain tumors
Cahan, M. A., Walter, K. A., Colvin, O. M., & Brem, H. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686276 · Cited by 116 · see citing works
LRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways
Langlois, B., Perrot, G., Schneider, C., Henriet, P., Emonard, H., Martiny, L., & Dedieu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011584 · Cited by 102 · see citing works
Phase II study of paclitaxel in patients with recurrent malignant glioma.
Prados, M. D., Schold, S. C., Spence, A. M., Berger, M. S., McAllister, L. D., Mehta, M. P., GILBERT, M. R., Fulton, D., Kuhn, J. G., Lamborn, K. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2316 · Cited by 97 · see citing works
Shih, H. (1980) · Chinese Studies in History · doi:10.2753/csh0009-4633140235 · Cited by 94 · see citing works
In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas
Fruehauf, J. P., Brem, H., Brem, S. S., Sloan, A. E., Barger, G. R., Huang, W., & Parker, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1830 · Cited by 78 · see citing works
Role of ABC Transporters in the Chemoresistance of Human Gliomas
Declèves, X., Benouaich‐Amiel, A., Delattre, J., & Scherrmann, J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723930 · Cited by 70 · see citing works
Fine, R. L., Chen, J., Balmaceda, C. M., Bruce, J. N., Huang, M., Desai, M., Sisti, M. B., McKhann, G. M., Goodman, R. R., Bertino, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2356 · Cited by 67 · see citing works
Tooyama, I., Kawamata, T., Akiyama, H., Kimura, H., Moestrup, S. K., Gliemann, J., Matsuo, A., & McGeer, P. L. (1995) · Brain Research · doi:10.1016/0006-8993(95)00735-9 · Cited by 56 · see citing works
Targeting the Brain – Surmounting or Bypassing the Blood–Brain Barrier
Potschka, H. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_14 · Cited by 45 · see citing works
Dedieu, S., & Langlois, B. (2008) · Cell Adhesion & Migration · doi:10.4161/cam.2.2.6374 · Cited by 44 · see citing works
The role of paclitaxel in the treatment of primary and metastatic brain tumors.
Glantz, M., Chamberlain, M. C., Chang, S., Prados, M. D., & Cole, B. F. (1999) · PubMed · Cited by 37 · see citing works
Treatment of recurrent high-grade gliomas
Wen, P. Y., & Brandes, A. A. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833229e3 · Cited by 36 · see citing works
Self-citationYamamoto, M., Ikeda, K., Ohshima, K., Tsugu, H., Kimura, H., & Tomonaga, M. (1998) · Brain Tumor Pathology · doi:10.1007/bf02482097 · Cited by 25 · see citing works
Liu, X., Wu, K.-C., Huang, Y., Sun, J.-B., Ke, X.-Y., Wang, J.-C., Lü, W.-L., Zhang, X., & Zhang, Q. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1215 · Cited by 15 · see citing works
Phase 1 Dose-Finding Trials and Fibonacci
OMURA, G. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1762 · Cited by 9 · see citing works
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,841 · see citing works
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · see citing works
Self-citationOvercoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035 · see citing works
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C. E., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 815 · see citing works
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604 · see citing works
Lin, X., & DeAngelis, L. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9503 · Cited by 446 · see citing works
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 443 · see citing works
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482 · see citing works
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399 · see citing works
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387 · see citing works
Brain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334 · see citing works
Oberoi, R. K., Parrish, K. E., Sio, T. T. W., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 283 · see citing works
Kumthekar, P., Tang, S., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C. K., Carrillo, J., Chalasani, P., Kabos, P., Puhalla, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3258 · Cited by 259 · see citing works
Self-citationPeptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Hoppenz, P., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00571 · Cited by 248 · see citing works
Zhou, X., Smith, Q. R., & Liu, X. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1695 · Cited by 218 · see citing works
Fu, C. S., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.020 · Cited by 211 · see citing works
Jiang, Y., Zhang, J., Meng, F., & Zhong, Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b05265 · Cited by 201 · see citing works
Komin, A., Russell, L. M., Hristova, K. A., & Searson, P. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.002 · Cited by 189 · see citing works
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182 · see citing works
Zhang, D. Y., Dmello, C., Chen, L., Arrieta, V. A., González-Buendía, E., KANE, J. R., Magnusson, L. P., Baran, A. H., James, C. D., Horbinski, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2182 · Cited by 176 · see citing works
Peptide–drug conjugate-based novel molecular drug delivery system in cancer
Zhu, Y., Tang, K., & Lv, J. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.07.001 · Cited by 157 · see citing works
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 152 · see citing works
Zhang, F., Xu, C., & Liu, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79592 · Cited by 147 · see citing works
Harder, B. G., Blomquist, M. R., Wang, J., Kim, A. J., Woodworth, G. F., Winkles, J. A., Loftus, J. C., & Tran, N. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00462 · Cited by 144 · see citing works
Antibody therapies in CNS diseases
Freskgård, P., & Urich, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.014 · Cited by 139 · see citing works
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131 · see citing works
Retro-Inverso Isomer of Angiopep-2: A Stable d -Peptide Ligand Inspires Brain-Targeted Drug Delivery
Wei, X., Zhan, C., Chen, X., Hou, J., Xie, C., & Lu, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500086e · Cited by 126 · see citing works
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L. E., Villanueva-Meyer, J. E., Winkler, E. A., & de Groot, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01338-x · Cited by 127 · see citing works
Horodyckid, C., Canney, M. S., Vignot, A., Boisgard, R., Drier, A., Huberfeld, G., François, C., Prigent, A., Santin, M. D., Adam, C., et al. (2016) · Journal of neurosurgery · doi:10.3171/2016.3.jns151635 · Cited by 124 · see citing works
Novel delivery methods bypassing the blood-brain and blood-tumor barriers
Hendricks, B. K., Cohen‐Gadol, A., & Miller, J. C. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14767 · Cited by 119 · see citing works
Régina, A., Demeule, M., Tripathy, S., Lord‐Dufour, S., Currie, J.-C., Iddir, M., Annabi, B., Castaigne, J., & Lachowicz, J. E. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0399 · Cited by 117 · see citing works
Self-citationConjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Demeule, M., Beaudet, N., Régina, A., Besserer‐Offroy, É., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70647 · Cited by 117 · see citing works
Self-citationAgile delivery of protein therapeutics to CNS
Yi, X., Manickam, D. S., Brynskikh, A. M., & Kabanov, A. V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.017 · Cited by 115 · see citing works
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
Razzak, R. A., Florence, G. J., & Gunn‐Moore, F. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123108 · Cited by 115 · see citing works
Targeting specific cells in the brain with nanomedicines for CNS therapies
Zhang, F., Lin, Y.-A., Kannan, S., & Kannan, R. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.013 · Cited by 110 · see citing works
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
He, R., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2019) · Molecules · doi:10.3390/molecules24101855 · Cited by 110 · see citing works
Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612931 · Cited by 109 · see citing works
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 102 · see citing works
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Mair, M. J., Bartsch, R., Rhun, É. L., Berghoff, A. S., Brastianos, P. K., Cortés, J., Gan, H. K., Lin, N., Lassman, A. B., Wen, P. Y., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00756-z · Cited by 104 · see citing works
Self-citationEngineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernández, Y. M., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 103 · see citing works
Peptide-Drug Conjugates: A New Hope for Cancer Management
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V., & Bojarska, J. (2022) · Molecules · doi:10.3390/molecules27217232 · Cited by 100 · see citing works
Receptor-Mediated Drug Delivery Systems Targeting to Glioma
Wang, S., Meng, Y., Li, C., Qian, M., & Huang, R. (2015) · Nanomaterials · doi:10.3390/nano6010003 · Cited by 95 · see citing works
Drug delivery and release systems for targeted tumor therapy
Böhme, D., & Beck‐Sickinger, A. G. (2015) · Journal of Peptide Science · doi:10.1002/psc.2753 · Cited by 94 · see citing works
Transcellular brain drug delivery: A review on recent advancements
Azarmi, M., Maleki, H., Nikkam, N., & Malekinejad, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119582 · Cited by 94 · see citing works
Peptide-decorated polymeric nanomedicines for precision cancer therapy
Sun, H., Dong, Y., Feijén, J., & Zhong, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.029 · Cited by 91 · see citing works
How to Make Anticancer Drugs Cross the Blood–Brain Barrier to Treat Brain Metastases
Angeli, E., Nguyen, T. T., Janin, A., & Bousquet, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010022 · Cited by 93 · see citing works
Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges
Parrasia, S., Szabó, I., Zoratti, M., & Biasutto, L. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00523 · Cited by 90 · see citing works
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89 · see citing works
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
Gilad, Y., Firer, M. A., & Gellerman, G. (2016) · Biomedicines · doi:10.3390/biomedicines4020011 · Cited by 87 · see citing works
Wang, L., Hao, Y., Li, H., Zhao, Y., Meng, D., Li, D., Shi, J., Zhang, H., Zhang, Z., & Zhang, Y. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1025077 · Cited by 87 · see citing works
Biomimetic drug-delivery systems for the management of brain diseases
Chen, Y., Wei, C., Lyu, Y., Chen, H., Jiang, G., & Gao, X. (2019) · Biomaterials Science · doi:10.1039/c9bm01395d · Cited by 86 · see citing works
Ahamed, J., Gowda, B. H. J., Almalki, W. H., Gupta, N., Sahebkar, A., & Kesharwani, P. (2023) · European Polymer Journal · doi:10.1016/j.eurpolymj.2023.112111 · Cited by 83 · see citing works
Balça-Silva, J., Matias, D., do Carmo, A., Sarmento‐Ribeiro, A. B., Lopes, M. C., & Moura‐Neto, V. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.007 · Cited by 83 · see citing works
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. P. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 81 · see citing works
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Vogelbaum, M. A., Krivosheya, D., Borghei-Razavi, H., Sanai, N., Weller, M., Wick, W., Soffietti, R., Reardon, D. A., Aghi, M. K., Galanis, E., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa149 · Cited by 74 · see citing works
Self-citationTargeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 73 · see citing works
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
Lindberg, J., Nilvebrant, J., Nygren, P., & Lehmann, F. (2021) · Molecules · doi:10.3390/molecules26196042 · Cited by 72 · see citing works
Shi, Y., Jiang, Y., Cao, J., Yang, W., Zhang, J., Meng, F., & Zhong, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.034 · Cited by 71 · see citing works
Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches
Yeini, E., Ofek, P., Albeck, N., Ajamil, D. R., Neufeld, L., Eldar‐Boock, A., Kleiner, R., Vaskovich‐Koubi, D., Koshrovski‐Michael, S., Dangoor, S. I., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000124 · Cited by 68 · see citing works
Papademetriou, I. T., & Porter, T. M. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.48 · Cited by 68 · see citing works
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 64 · see citing works
Markowicz-Piasecka, M., Markiewicz, A., Darłak, P., Sikora, J., Adla, S. K., Bagina, S., & Huttunen, K. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01228-5 · Cited by 68 · see citing works
Wang, D., Yin, F., Li, Z., Zhang, Y., & Chen, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03277-2 · Cited by 69 · see citing works
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging
Ayo, A., & Laakkonen, P. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040481 · Cited by 64 · see citing works
Wu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59 · see citing works
Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes
Vetter, V. C., & Wagner, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.013 · Cited by 59 · see citing works
Gool, B. V., Dedieu, S., Emonard, H., & Roebroek, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00271 · Cited by 59 · see citing works
Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma
Branco, F., Cunha, J., Mendes, M., Vitorino, C., & Sousa, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c01790 · Cited by 58 · see citing works
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Rizvi, S. F. A., Zhang, L., Zhang, H., & Fang, Q. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00269 · Cited by 57 · see citing works
Peptide Shuttles for Blood–Brain Barrier Drug Delivery
Sánchez‐Navarro, M., & Giralt, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091874 · Cited by 56 · see citing works
Gao, X., Xu, J., Yao, T., Liu, X., Zhang, H., & Zhan, C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114362 · Cited by 55 · see citing works
Wu, Y., & Angelova, A. (2023) · Nanomaterials · doi:10.3390/nano13233004 · Cited by 53 · see citing works
Breaching the Blood–Brain Tumor Barrier for Tumor Therapy
Marcucci, F., Corti, A., & Ferreri, A. J. M. (2021) · Cancers · doi:10.3390/cancers13102391 · Cited by 51 · see citing works
Li, F., & Tang, S.-C. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.01.004 · Cited by 47 · see citing works
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Parakh, S., Nicolazzo, J. A., Scott, A. M., & Gan, H. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.718590 · Cited by 46 · see citing works
Sardoiwala, M. N., Kaundal, B., & Choudhury, S. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813351-4.00038-9 · Cited by 46 · see citing works
BBPpredict: A Web Service for Identifying Blood-Brain Barrier Penetrating Peptides
Chen, X., Zhang, Q., Li, B., Lu, C., Yang, S., Long, J., He, B., Chen, H., & Huang, J. H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.845747 · Cited by 42 · see citing works
Tincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 42 · see citing works
Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review
Zottel, A., Jovčevska, I., Šamec, N., & Komel, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103283 · Cited by 40 · see citing works
Zhang, Q., Liu, N., Wang, J., Liu, Y., Wang, K., Zhang, J., & Pan, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00629 · Cited by 40 · see citing works
Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies
ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J., & Broekman, M. L. D. (2024) · Cells · doi:10.3390/cells13120998 · Cited by 40 · see citing works
O'Sullivan, C. C., Lindenberg, M. L., Bryla, C., Patronas, N., Peer, C. J., Amiri‐Kordestani, L., Davarpanah, N. N., Gonzalez, E. M., Burotto, M., Choyke, P. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3972-z · Cited by 40 · see citing works
Nanocarrier drugs in the treatment of brain tumors
Černá, T., Stiborová, M., Adam, V., Kizek, R., & Eckschlager, T. (2016) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2015.95 · Cited by 40 · see citing works
Prodrugs as drug delivery system in oncology
Delahousse, J., Skarbek, C., & Paci, A. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03906-2 · Cited by 40 · see citing works
Peptide based drug delivery systems to the brain
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. R., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2020) · Nano Express · doi:10.1088/2632-959x/ab9008 · Cited by 40 · see citing works
Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma
Sun, B., Li, R., Ji, N., Liu, H., Wang, H., Chen, C., Bai, L., Su, J., & Chen, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101443 · Cited by 39 · see citing works
Targeting Tumors with Small Molecule Peptides
Cheetham, A. G., Keith, D., Zhang, P., Lin, R., Su, H., & Cui, H. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151130214646 · Cited by 37 · see citing works
Pinkiewicz, M., Pinkiewicz, M., Walecki, J. M., & Zawadzki, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950167 · Cited by 35 · see citing works
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 34 · see citing works
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33 · see citing works
Chen, X., Luo, X., Yin, W., Cui, W., He, Y., Tian, T., & Lin, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c03945 · Cited by 36 · see citing works
Overcoming the blood–brain barrier in neurodegenerative disorders and brain tumours
Ebrahimi, Z., Talaei, S., Aghamiri, S., Goradel, N. H., Jafarpour, A., & Negahdari, B. (2020) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2019.0351 · Cited by 32 · see citing works
Targeted Glioma Therapy—Clinical Trials and Future Directions
Shikalov, A. B., Koman, I. E., & Kogan, N. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010100 · Cited by 31 · see citing works
Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment
Jourdain, M. A., & Eyer, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.037 · Cited by 29 · see citing works
Pinkiewicz, M., Zaczyński, A., Walecki, J. M., & Zawadzki, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157050 · Cited by 33 · see citing works
Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases
Lim, M., Puttick, S. G., Houston, Z. H., Thurecht, K. J., Croft, P. K., Mahler, S. M., Rose, S., Jeffree, R. L., Mazzieri, R., Dolcetti, R., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061280 · Cited by 30 · see citing works
Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Rizvi, S. F. A., Zhang, H., & Fang, Q. (2024) · Medicinal Research Reviews · doi:10.1002/med.22046 · Cited by 30 · see citing works
Novel chemotherapeutics and other therapies for treating high-grade glioma
Kang, J. H., & Adamson, C. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1048332 · Cited by 28 · see citing works
Dendrimer-based magnetic resonance imaging agents for brain cancer
Ding, L., Lyu, Z., Dhumal, D. M., Kao, C., Bernard, M., & Peng, L. (2018) · Science China Materials · doi:10.1007/s40843-018-9323-6 · Cited by 28 · see citing works
Brain metastasis models: What should we aim to achieve better treatments?
Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 26 · see citing works
- Authors
- Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., Fielding, R. M., Elian, K., Wang, X., Lawrence, B., Shing, M., Kelsey, S., Castaigne, J. P., & Wen, P. Y.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2013-03-14
- Volume
- 19
- Issue
- 6
- Pages
- 1567-1576
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2111631341
- Cited by
- 190
- References
- 51
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 15 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 6 · 2016: 15 · 2015: 18 · 2014: 7 · 2013: 1
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- recurrent malignant glioma, peptide-drug conjugates, LDL receptor-related protein 1, blood-brain barrier penetration, paclitaxel, maximum tolerated dose, pharmacokinetics, dose-limiting toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Blood-Brain Barrier, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Peptides, Paclitaxel, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
